
	Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company&#39;s proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark&trade;&mdash;its prostate cancer prognostic test&mdash;through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company&#39;s Website at www.metamarkgenetics.com. Metamark&trade; and ProMark&trade; are trademarks of Metamark Genetics, Inc.
